JP2020521470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521470A5 JP2020521470A5 JP2019565334A JP2019565334A JP2020521470A5 JP 2020521470 A5 JP2020521470 A5 JP 2020521470A5 JP 2019565334 A JP2019565334 A JP 2019565334A JP 2019565334 A JP2019565334 A JP 2019565334A JP 2020521470 A5 JP2020521470 A5 JP 2020521470A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- deletion
- recombinant adenovirus
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 118
- 239000002773 nucleotide Substances 0.000 claims 60
- 230000037430 deletion Effects 0.000 claims 59
- 238000012217 deletion Methods 0.000 claims 59
- 125000003729 nucleotide group Chemical group 0.000 claims 59
- 241000701161 unidentified adenovirus Species 0.000 claims 47
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 108700019146 Transgenes Proteins 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- -1 tibozantinib Chemical compound 0.000 claims 10
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000037431 insertion Effects 0.000 claims 7
- 238000003780 insertion Methods 0.000 claims 7
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 230000003463 hyperproliferative effect Effects 0.000 claims 5
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 claims 4
- 102400000068 Angiostatin Human genes 0.000 claims 4
- 108010079709 Angiostatins Proteins 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 102400001047 Endostatin Human genes 0.000 claims 4
- 108010079505 Endostatins Proteins 0.000 claims 4
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 108700026226 TATA Box Proteins 0.000 claims 4
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 4
- 229960000397 bevacizumab Drugs 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 3
- 102100032187 Androgen receptor Human genes 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims 3
- 108010010995 MART-1 Antigen Proteins 0.000 claims 3
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 3
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 3
- 108010008707 Mucin-1 Proteins 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 3
- 101800001271 Surface protein Proteins 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 102000003425 Tyrosinase Human genes 0.000 claims 3
- 108060008724 Tyrosinase Proteins 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 229960003005 axitinib Drugs 0.000 claims 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 3
- 208000024519 eye neoplasm Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims 2
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 101150021185 FGF gene Proteins 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 102000000646 Interleukin-3 Human genes 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 102000000743 Interleukin-5 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- 102000000585 Interleukin-9 Human genes 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 2
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 101150048468 PODXL gene Proteins 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims 2
- 108020004440 Thymidine kinase Proteins 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 108050003627 Wnt Proteins 0.000 claims 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 2
- 229960004373 acetylcholine Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 201000000220 brain stem cancer Diseases 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 230000000112 colonic effect Effects 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 201000002491 encephalomyelitis Diseases 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 102000003898 interleukin-24 Human genes 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960000639 pazopanib Drugs 0.000 claims 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 102000004401 podocalyxin Human genes 0.000 claims 2
- 108090000917 podocalyxin Proteins 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 229960000940 tivozanib Drugs 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 claims 1
- 101710113110 B-cell receptor-associated protein 31 Proteins 0.000 claims 1
- 102000039506 BAGE family Human genes 0.000 claims 1
- 108091067183 BAGE family Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims 1
- 108010062745 Chloride Channels Proteins 0.000 claims 1
- 102000011045 Chloride Channels Human genes 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 101710130332 ETS domain-containing protein Elk-4 Proteins 0.000 claims 1
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 108010055191 EphA3 Receptor Proteins 0.000 claims 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000040452 GAGE family Human genes 0.000 claims 1
- 108091072337 GAGE family Proteins 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 claims 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims 1
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 1
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 1
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 claims 1
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 claims 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims 1
- 101001109282 Homo sapiens NudC domain-containing protein 1 Proteins 0.000 claims 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 claims 1
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 101710139711 IkB-like protein Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 1
- 101710081123 Interleukin-27 subunit alpha Proteins 0.000 claims 1
- 101710116301 Interleukin-27 subunit beta Proteins 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 102000002297 Laminin Receptors Human genes 0.000 claims 1
- 108010000851 Laminin Receptors Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 claims 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 108010063954 Mucins Proteins 0.000 claims 1
- 102000015728 Mucins Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100022475 NudC domain-containing protein 1 Human genes 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 108010058860 P.polypeptide Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 101710138742 Receptor-type tyrosine-protein phosphatase H Proteins 0.000 claims 1
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 claims 1
- 102400000830 Saposin-B Human genes 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 101150006914 TRP1 gene Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229950002216 linifanib Drugs 0.000 claims 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000316 virotherapy Methods 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023037694A JP2023063392A (ja) | 2017-05-24 | 2023-03-10 | 抗脈管形成アデノウイルス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510647P | 2017-05-24 | 2017-05-24 | |
| US62/510,647 | 2017-05-24 | ||
| US201762514351P | 2017-06-02 | 2017-06-02 | |
| US62/514,351 | 2017-06-02 | ||
| PCT/US2018/034487 WO2018218083A1 (en) | 2017-05-24 | 2018-05-24 | Anti-angiogenic adenovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023037694A Division JP2023063392A (ja) | 2017-05-24 | 2023-03-10 | 抗脈管形成アデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521470A JP2020521470A (ja) | 2020-07-27 |
| JP2020521470A5 true JP2020521470A5 (enExample) | 2021-07-26 |
| JP7245175B2 JP7245175B2 (ja) | 2023-03-23 |
Family
ID=64396026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565334A Active JP7245175B2 (ja) | 2017-05-24 | 2018-05-24 | 抗脈管形成アデノウイルス |
| JP2023037694A Pending JP2023063392A (ja) | 2017-05-24 | 2023-03-10 | 抗脈管形成アデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023037694A Pending JP2023063392A (ja) | 2017-05-24 | 2023-03-10 | 抗脈管形成アデノウイルス |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200155625A1 (enExample) |
| EP (1) | EP3630959A4 (enExample) |
| JP (2) | JP7245175B2 (enExample) |
| KR (1) | KR20200020723A (enExample) |
| CN (1) | CN111448309A (enExample) |
| AU (1) | AU2018271999A1 (enExample) |
| CA (1) | CA3064892A1 (enExample) |
| MX (1) | MX2019014059A (enExample) |
| WO (1) | WO2018218083A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN110295195A (zh) * | 2019-06-26 | 2019-10-01 | 浙江理工大学 | 靶向肝癌的溶瘤腺病毒gd55-gsdme的构建和应用 |
| EP4162060A4 (en) * | 2020-06-05 | 2024-09-11 | EpicentRx, Inc. | Mono- and multi-valent sars-cov-2 adenoviral vector vaccines and sars-cov-2 immune globulin and methods of use |
| CN115120744B (zh) * | 2021-03-24 | 2025-01-28 | 四川大学 | 重组人内皮抑素腺病毒与抗pd-1抗体或抗pd-l1抗体在制备抗肿瘤药物中的用途 |
| CN114931634B (zh) * | 2022-03-18 | 2023-03-17 | 广州达博生物制品有限公司 | E10a与pd1单抗对肿瘤的联合治疗方法和制药用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183250C (zh) * | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| AU2002256388A1 (en) * | 2001-04-30 | 2002-11-11 | Cell Genesys, Inc. | Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| AU2006203736B2 (en) * | 2004-12-31 | 2012-03-29 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| KR100896483B1 (ko) * | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| PT2403951E (pt) * | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| SG11201906973TA (en) * | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
-
2018
- 2018-05-24 EP EP18806701.1A patent/EP3630959A4/en active Pending
- 2018-05-24 WO PCT/US2018/034487 patent/WO2018218083A1/en not_active Ceased
- 2018-05-24 CA CA3064892A patent/CA3064892A1/en active Pending
- 2018-05-24 AU AU2018271999A patent/AU2018271999A1/en not_active Abandoned
- 2018-05-24 KR KR1020197037967A patent/KR20200020723A/ko not_active Ceased
- 2018-05-24 US US16/616,146 patent/US20200155625A1/en not_active Abandoned
- 2018-05-24 MX MX2019014059A patent/MX2019014059A/es unknown
- 2018-05-24 CN CN201880051792.1A patent/CN111448309A/zh active Pending
- 2018-05-24 JP JP2019565334A patent/JP7245175B2/ja active Active
-
2023
- 2023-03-10 JP JP2023037694A patent/JP2023063392A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521470A5 (enExample) | ||
| Coccolini et al. | Advanced gastric cancer: what we know and what we still have to learn | |
| Seifert et al. | Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice | |
| Sideras et al. | Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| Yang et al. | Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy | |
| JP7245175B2 (ja) | 抗脈管形成アデノウイルス | |
| JP2020516293A5 (enExample) | ||
| JP2020510624A5 (enExample) | ||
| JP2020505049A5 (enExample) | ||
| RU2019136640A (ru) | Композиции с улучшенными т-клетками и способы | |
| JP2016537417A (ja) | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法 | |
| JP2015506704A5 (enExample) | ||
| JP2016513458A5 (enExample) | ||
| AU2021203142B2 (en) | Anticancer Composition Comprising Recombinant Adenovirus Expressing Degradation Factor For Extracellular Matrix | |
| Wojtowicz et al. | Immunologic approaches to cancer prevention—current status, challenges, and future perspectives | |
| JP2020517261A5 (enExample) | ||
| Rodriguez-Garcia et al. | T-cell target antigens across major gynecologic cancers | |
| Azadi et al. | Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines | |
| CN111050790A (zh) | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 | |
| Tu et al. | Advances in immunotherapy for gynecological malignancies | |
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| Suckow | Cancer vaccines: harnessing the potential of anti-tumor immunity | |
| Wang et al. | Induced pluripotent stem cells as a novel cancer vaccine | |
| Fleischmann et al. | Radioimmunotherapy: future prospects from the perspective of brachytherapy |